Sanofi pegs U.S. drug price rises to below healthcare inflation

(Reuters) - French drugmaker Sanofi has pledged to peg U.S. drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5.4 percent, unless there are exceptional circumstances.

Sanofi pegs U.S. drug price rises to below healthcare inflation
Read More


Bagikan Berita Ini